灵活把握A+H超额收益 行业均衡型基金受青睐

Group 1 - In August, A-shares led global stock markets, with equity funds performing well, particularly those focused on the TMT (Technology, Media, and Telecommunications) sector, while pharmaceutical sector funds saw declines [1] - A total of 32 equity funds achieved returns exceeding 40% in August, indicating a significant shift in market dynamics [1] - The "霸榜" (top ranking) trend previously dominated by the North Exchange and pharmaceutical-themed funds has changed, with technology-heavy funds now leading [1] Group 2 - The fund managed by Wu Yuanyi, Guangfa Value Core A, achieved a nearly one-year return of 101.36% as of September 5, outperforming its benchmark by 67.56% with a Sharpe ratio of 2.66 [1] - Guangfa Value Core A, established in January 2021, is a full-market fund that can invest in A-shares and Hong Kong Stock Connect, showcasing a stable stock position and diversified industry allocation [1] - The fund's top ten holdings account for approximately 50% of its net value, with a balanced distribution across various sectors including pharmaceuticals, automotive, electronics, textiles, machinery, and computers [1] Group 3 - Wu Yuanyi dynamically adjusts the stock allocation between A-shares and Hong Kong stocks based on market conditions, increasing the Hong Kong stock allocation from about 11% at the end of Q1 2024 to over 31% by the end of Q4 2024 [2] - The fund has effectively captured both beta and alpha returns in the recent Hong Kong market rally, focusing on innovative pharmaceuticals and new consumption sectors [2] - Recent quarterly reports indicate strong performance from newly added stocks, with significant price increases for stocks like Weixin Bio and Haoyuan Pharmaceutical, showcasing effective stock selection capabilities [2] Group 4 - Looking ahead, the focus will be on fast-moving consumer goods, innovative pharmaceuticals, high-end manufacturing, robotics, and AI sectors [3] - The fast-moving consumer goods sector is recovering first due to its "high frequency and low price" characteristics [3] - In the pharmaceutical innovation sector, China is transitioning from auxiliary research to becoming a global leader in original innovative drugs [3]